Predictive Technology Group Engages CLSA Capital Markets Limited, a CITIC Securities Company, to Support Product Launches into China’s Rapidly Growing Women’s Health and Fertility Market
October 15, 2019 09:00 ET | Source: Predictive Technology Group, Inc.
SALT LAKE CITY, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announces that it has engaged CLSA Capital Markets Limited, a CITIC Securities Company, to provide introductions to potential strategic partners and regulatory guidance to support the launch of its proprietary genetic-based products into China’s (PRC) rapidly growing markets for women’s health and fertility. Terms of the transaction were not disclosed.
“Given our genetic library, research and understanding of genetics, endometriosis and other factors that may affect a woman’s fertility, we are excited to bring our noninvasive testing technology to this large, emerging market that already surpasses the U.S. in terms of the number of affected women,” said Bradley Robinson, Chief Executive Officer of Predictive Technology Group. “Our tests help both the doctor and patient understand and navigate the barriers to fertility, changing the path to a healthy baby. We are especially pleased to collaborate in this endeavor with CLSA, a leading capital markets and investment group in Asia.”
Predictive expects to introduce ARTguide™ among other fertility diagnostics to the Chinese market. On October 14, 2019, Predictive launched the full U.S. market availability of ARTguide, its test to evaluate the risk for endometriosis and other genetic causes of infertility in women, at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo in Philadelphia.
In 2016 the National Health and Family Planning Commission of the PRC reported that 40 million Chinese couples were experiencing fertility issues. Similarly, the American Society for Reproductive Medicine (ASRM) reported in 2017 that an estimated 25% of Chinese women of childbearing age struggled with infertility issues. In 2018 the European Society of Human Reproduction and Embryology estimated that approximately 800,000 assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), were being performed in China annually. Chinese women are driving the fertility markets both in China and medical tourism industries overseas. The global IVF market is expected to grow at an annual rate of 10.2% and to reach $36.2 billion by 2026. The U.S. Center for Disease Control reported that of the patients who sought fertility care in 2017, 284,385 ART cycles were performed resulting in 78,052 live born infants with ART accounting for 1.7% of all infants born in the U.S. annually.
Predictive Laboratories ARTguide Test
ARTguide is the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women. It provides a greater understanding of over a dozen genetic conditions affecting a woman’s fertility by identifying previously invisible barriers to conception, consequently improving ART success rates. ARTguide is appropriate for all women considering use of ART to overcome difficulty conceiving or carrying a pregnancy.
ARTguide was introduced to a limited number of U.S. clinics in 2018. Predictive Laboratories is a wholly owned molecular and genetic diagnostics company of Predictive Technology Group focused on hard-to-detect diseases, women’s health and infertility. Predictive Laboratories recently completed a laboratory expansion to add capacity that allows ARTguide to be available more broadly in the U.S.
Endometriosis
Endometriosis is an estrogen-responsive, chronic condition that arises from extra-uterine growth of the stromal or glandular tissue that line the uterus. Often called the “invisible disease,” endometriosis affects an estimated 1 in 10 women in the U.S. during their reproductive years with many cases go undiagnosed. It is common for a woman to experience symptoms—such as chronic pelvic pain, heavy or painful periods—for a decade or more before a diagnosis is made (13 years, on average, in China). The current standard for diagnosis is laparoscopic surgery, to biopsy lesions found within the fallopian tubes or uterus. Even with this surgery, intraoperative diagnosis by conventional laparoscopic visualization is frequently difficult and inaccurate.
Severe endometriosis with extensive scarring and organ damage is one of the most common causes of female infertility. However, endometriosis can still affect fertility when no symptoms are present. 30% to 50% of women with endometriosis may experience infertility, and 25% to 50% of women who experience infertility have endometriosis.
Studies have linked the risk of endometriosis to ethnicity, with several reporting Asian women’s risk being nine times greater than that of Caucasian women. A recent systematic review analyzing the outcomes of more than 1.9 million Chinese women found endometriosis to be associated with the worsening of obstetric and pregnancy-related outcomes, including miscarriage, pre-term labor, placenta previa, small for gestational age, and caesarean delivery compared to healthy controls.
Predictive Laboratories, Inc.
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis. For more information, visit www.predictivelabs.com.
Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
CLSA Capital Markets Limited
CLSA is Asia’s leading capital markets and investment group, providing global investors with insights, liquidity, and capital to drive their investment strategies. Award-winning research, an extensive Asia footprint, direct links to China, and highly experienced finance professionals differentiate our innovative products and services in asset management, corporate finance, capital, and debt markets, securities, and wealth management. As the international platform of CITIC Securities (SSE: 600030, SEHK: 6030), China’s largest investment bank, CLSA is uniquely positioned to facilitate cross-border capital flows and connect China with the world and the world to China. Founded in 1986 and headquartered in Hong Kong, CLSA’s global network spans 21 locations across Asia, Australia, Europe, and the United States. For more information, visit www.clsa.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts
For more information, visit www.predtechgroup.com or contact Investor Relations:
Media Contact
Holly Dugan
predictive@antennagroup.com
201-465-8019
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
Predictive Laboratories Team Led by Laboratory Director Kenneth Ward, M.D. Receives 2019 Endometriosis Special Interest Group Prize Paper Award
Research presented by Dr. Hans Albertsen of Juneau Biosciences advancing knowledge of the genetic factors contributing to endometriosis receives award at the 2019 American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo
Email Print Friendly Share
October 17, 2019 09:00 ET | Source: Predictive Technology Group, Inc.
SALT LAKE CITY , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces Kenneth Ward, M.D., laboratory director of Predictive Laboratories and chief executive officer of Juneau Biosciences; Rakesh Chettier M.S., director of biostatistics of Predictive Laboratories; and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences, have received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science” category.
Dr. Albertsen’s presentation entitled “Cytoskeletal and extra cellular matrix genes are key contributors in the pathogenesis of endometriosis” was delivered at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo in Philadelphia on October 16. EndoSIG is a member group of ASRM aimed at fostering increased interest in the biology, pathophysiology and clinical management of endometriosis.
“We are honored to receive this prestigious award from the ASRM Research Committee,” said Dr. Albertsen. “As endometriosis is generally characterized as a hormonal and inflammatory disease, current therapies often come with significant debilitating side effects. The scientific breakthroughs reported in these award-winning discoveries provide Predictive with insights into new non-hormonal therapies.”
The team’s research is based on the genetic markers of endometriosis discovered by Juneau and Predictive scientists in recent years, and uncovers molecular pathways involved in the pathogenesis of endometriosis-induced lesions in women at risk for the disease. Juneau’s gene discovery work in endometriosis was also awarded the EndoSIG Prize Paper in 2015 and 2018.
Dr. Ward, a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics, presented two scientific papers at the Annual ASRM meeting: a poster entitled, “Endometriosis risk allele in WNT4 may interact with rare mutations in HDAC2 gene” and an oral abstract entitled, “Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk.”
“We are tremendously proud of Drs. Ward and Albertsen and the teams at Predictive Laboratories and Juneau Biosciences for their research, collaborations and continued devotion to endometriosis and other gene discoveries that advance our understanding of fertility and women’s health, and lead to healthy newborns,” said Bradley Robinson, chief executive officer of Predictive Technology Group. “ASRM brings leaders in reproductive care together from across the world to share findings, inspire new methodology and encourage collaboration to promote further development in reproductive medicine.”
In June 2019, Predictive Laboratories and Thermo Fisher Scientific announced a global research collaboration to study underlying genetic factors contributing to female infertility. The two companies conducted meetings at ASRM in Philadelphia. This partnership pairs Predictive’s innovative research and development capabilities with Thermo Fisher’s market-leading next generation sequencing technology and analytical capabilities to accelerate the understanding of the genetics affecting infertility for future development of diagnostic solutions.
About Predictive Laboratories
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
The Company’s proprietary tests include ARTguide[SUP]TM[/SUP] and FertilityDX[SUP]TM[/SUP]. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts
For more information, visit www.predtechgroup.com or contact Investor Relations:
Media Contact
Holly Dugan
predictive@antennagroup.com
201-465-8019
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
Hey Bruce. I followed you in this pretty blindly and got in at like $1.50 a share in 2018 and then rode it up to like $6 a share earlier this year. Thank you for that. I made some profit and kept some shares. Frankly though it seems like a pump and dumper. I see
when you copy and paste articles widely available from yahoo finance news wires but does your gut tell you this thing is going to rise back up or is it just time to dump remaining shares. Like a lotta healthcare/biotech/tech related stuff, it’s getting hammered. Just looking for you opinion on whether to hold on, dump, or maybe even double down. Thx man.
when you copy and paste articles widely available from yahoo finance news wires but does your gut tell you this thing is going to rise back up or is it just time to dump remaining shares. Like a lotta healthcare/biotech/tech related stuff, it’s getting hammered. Just looking for you opinion on whether to hold on, dump, or maybe even double down. Thx man.
Hey Bruce. I followed you in this pretty blindly and got in at like $1.50 a share in 2018 and then rode it up to like $6 a share earlier this year. Thank you for that. I made some profit and kept some shares. Frankly though it seems like a pump and dumper. I see
when you copy and paste articles widely available from yahoo finance news wires but does your gut tell you this thing is going to rise back up or is it just time to dump remaining shares. Like a lotta healthcare/biotech/tech related stuff, it’s getting hammered. Just looking for you opinion on whether to hold on, dump, or maybe even double down. Thx man.
when you copy and paste articles widely available from yahoo finance news wires but does your gut tell you this thing is going to rise back up or is it just time to dump remaining shares. Like a lotta healthcare/biotech/tech related stuff, it’s getting hammered. Just looking for you opinion on whether to hold on, dump, or maybe even double down. Thx man.
The stock trades like crap. Fact. When we lost support the selling continued pushing us back down . This all started from a report full of lies by the shorts . We never got listed and here we are
I should have sold every share at 6 and bought it back here blah blah
I’m in to see 100
if your concerned , go reread the press releases , do your research on the Management, and the size and scope of the global marketplace for their products
technically we are way oversold , and showing a triple bottom at 1.15. Let’s see if we can rally from this condition
think or swim showing earnings again 11/14 ( remember , it’s still on the pink sheets so these dates are not exactly etched in stone )
this is is a true long term investment fir me and all about the upside
I know I said this before but I believe it
until they get listed on a major exchange it’s like investing in a private company pre-Ipo
Let’s see where the stock price is when we do 500,000 in sales ( or more )
I should have sold every share at 6 and bought it back here blah blah
I’m in to see 100
if your concerned , go reread the press releases , do your research on the Management, and the size and scope of the global marketplace for their products
technically we are way oversold , and showing a triple bottom at 1.15. Let’s see if we can rally from this condition
think or swim showing earnings again 11/14 ( remember , it’s still on the pink sheets so these dates are not exactly etched in stone )
this is is a true long term investment fir me and all about the upside
I know I said this before but I believe it
until they get listed on a major exchange it’s like investing in a private company pre-Ipo
Let’s see where the stock price is when we do 500,000 in sales ( or more )
My name is Johnny Mackey https://www.linkedin.com/in/john-mackey/ and I toured Predictive Technologies biotech division escorted by Eric Olsen (President and CEO) https://www.linkedin.com/in/eric-kenneth-olson-01725396/ I did this on behalf of Thetalus Capital LLC (Managing Partner's Adam Tischer, and John Mackey. A Nevada hedge fund LLC; document # 20190251769-02).
In order to placate said Hedge investors, to which they have a fiduciary duty in their LLC because of recent naked shorts, John Mackey and Adam Tischer commissioned me to take a closer look at the company. Do they have a real location? A real product? What about the staff? Payroll? Or is it all a scam as Hindenburg et all have previously proposed.
Predictive technologies is a real company, with a real product, and real revenue. Deloitte was auditing the company even as Hindenburg was busy writing their defamatory articles and illegally shorting. It is plainly seen on the volume when these naked shorts appear. I wouldn't be surprised if legal proceedings, including jail time were in the works on behalf of Predictive and other investor's as a class action, particularly against the trade platforms and brokers facilitating them, because Predictive truly does have a stellar team. Winning awards at the ASRM conference just a few days before my tour.
Thetalus capital is in discussions to recover said money against naked shorts. The evidence they are collecting is public, and evidence is being collected against Fidelity junior broker's that have advised clients to illegally short.
While I was touring their lab (I am an analytical chemist by trade, and a subject matter expert on drug launches and FDA compliance), I saw teams of technicians and scientists busy at work cutting umblical cords to extract Stem Cells. The lab was immaculate (I was told it is ISO 5, and some parts are ISO 7 in the surrounding facilities) and the lab was in the process of obtaining more ISO certification (15189 I think Eric said?).
Most of the Board has strong connections to the University of Utah (one of the best university hospitals in the world). In fact, they share a building with the University of Utah Endocrinology and diabetes building, and have poached a large portion of their staff from former University of Utah hospital admin, taking their best and brightest.
I would estimate a payroll of about 120 employees. This does not include contract lab testing or sales staff. There were about 25-30 in the biotech building I toured busy at work (Suite 300 of 615 Arapeen Dr, Salt Lake City UT 84105)
There could be no better fit than Kenneth Ward as lab director https://www.linkedin.com/in/kenneth-ward-58201910/ , who is a long time peer of Eric Olsen as well.
While the Stem Cell pain management is the main source of revenue for Predictive, there have been an enormous amount of public announcements about Endometriosis products, including Fertility DX, and the ARTguide. A spirit of optimism abounds in the building.
Eric couldn't give out non-public information about sales, but optimism by him and the staff abounds. I was told to pay close attention to the next 10K filings about their newer products sales trajectories.
Of particular interest to Thetalus Capital has been the CLSA venture into China announced 10/15. This hard to reach exclusive market could prove extremely valuable to Predictive Technologies as they are the first endometriosis treatment "in" inside the country of any substance. This was quite a hat trick indeed.
As much as Eric Olsen was able to disclose, their Nasdaq listing is on track. They anticipate it shortly after they can get the stock to close above the required price. Deloitte has been instrumental in helping their Nasdaq listing, and making sure they are ready to go once the trigger has been pulled.
My recommendation as a scientist in pharmaceuticals was to maintain or even increase Thetalus's capital's position (The LLC has operating agreement rules that limit their investments as a %, but with the decrease in price may allow them to increase their position). Stem cell pain management will grow exponentially (10K filings of PRED show a 160% or more growth for a large company.) As this explosive growth trading at 10x Sales of a growth company is a no brainer.
I witnessed Umblical Cord splicing. These technicians weren't putting on a show (I interned at the University of Utah's medical lab testing ARUP Clinical Toxicology 3 lab under Chantry Clark https://www.linkedin.com/in/chantry-clark-18739878/ , which included Umbilical cord slicing)
This complicated business is being navigated successfully by the PRED staff. Most had MBA's, MHA's, MD's and other accreditation's.
World class staff. Couldn't be run by anyone better.
I would advise the shorts: prepare for poverty and jail time.
In order to placate said Hedge investors, to which they have a fiduciary duty in their LLC because of recent naked shorts, John Mackey and Adam Tischer commissioned me to take a closer look at the company. Do they have a real location? A real product? What about the staff? Payroll? Or is it all a scam as Hindenburg et all have previously proposed.
Predictive technologies is a real company, with a real product, and real revenue. Deloitte was auditing the company even as Hindenburg was busy writing their defamatory articles and illegally shorting. It is plainly seen on the volume when these naked shorts appear. I wouldn't be surprised if legal proceedings, including jail time were in the works on behalf of Predictive and other investor's as a class action, particularly against the trade platforms and brokers facilitating them, because Predictive truly does have a stellar team. Winning awards at the ASRM conference just a few days before my tour.
Thetalus capital is in discussions to recover said money against naked shorts. The evidence they are collecting is public, and evidence is being collected against Fidelity junior broker's that have advised clients to illegally short.
While I was touring their lab (I am an analytical chemist by trade, and a subject matter expert on drug launches and FDA compliance), I saw teams of technicians and scientists busy at work cutting umblical cords to extract Stem Cells. The lab was immaculate (I was told it is ISO 5, and some parts are ISO 7 in the surrounding facilities) and the lab was in the process of obtaining more ISO certification (15189 I think Eric said?).
Most of the Board has strong connections to the University of Utah (one of the best university hospitals in the world). In fact, they share a building with the University of Utah Endocrinology and diabetes building, and have poached a large portion of their staff from former University of Utah hospital admin, taking their best and brightest.
I would estimate a payroll of about 120 employees. This does not include contract lab testing or sales staff. There were about 25-30 in the biotech building I toured busy at work (Suite 300 of 615 Arapeen Dr, Salt Lake City UT 84105)
There could be no better fit than Kenneth Ward as lab director https://www.linkedin.com/in/kenneth-ward-58201910/ , who is a long time peer of Eric Olsen as well.
While the Stem Cell pain management is the main source of revenue for Predictive, there have been an enormous amount of public announcements about Endometriosis products, including Fertility DX, and the ARTguide. A spirit of optimism abounds in the building.
Eric couldn't give out non-public information about sales, but optimism by him and the staff abounds. I was told to pay close attention to the next 10K filings about their newer products sales trajectories.
Of particular interest to Thetalus Capital has been the CLSA venture into China announced 10/15. This hard to reach exclusive market could prove extremely valuable to Predictive Technologies as they are the first endometriosis treatment "in" inside the country of any substance. This was quite a hat trick indeed.
As much as Eric Olsen was able to disclose, their Nasdaq listing is on track. They anticipate it shortly after they can get the stock to close above the required price. Deloitte has been instrumental in helping their Nasdaq listing, and making sure they are ready to go once the trigger has been pulled.
My recommendation as a scientist in pharmaceuticals was to maintain or even increase Thetalus's capital's position (The LLC has operating agreement rules that limit their investments as a %, but with the decrease in price may allow them to increase their position). Stem cell pain management will grow exponentially (10K filings of PRED show a 160% or more growth for a large company.) As this explosive growth trading at 10x Sales of a growth company is a no brainer.
I witnessed Umblical Cord splicing. These technicians weren't putting on a show (I interned at the University of Utah's medical lab testing ARUP Clinical Toxicology 3 lab under Chantry Clark https://www.linkedin.com/in/chantry-clark-18739878/ , which included Umbilical cord slicing)
This complicated business is being navigated successfully by the PRED staff. Most had MBA's, MHA's, MD's and other accreditation's.
World class staff. Couldn't be run by anyone better.
I would advise the shorts: prepare for poverty and jail time.
Predictive Technologies Group PRED Upgrades to OTCQX® Best Market
Email Print Friendly Share
October 24, 2019 07:00 ET | Source: Predictive Technology Group Inc
SALT LAKE CITY, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCQX: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced that the company has been upgraded to the OTCQX® Best Market from the Pink® market. Effective today, the company’s shares will trade under the ticker “PRED.” U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
“We are pleased to upgrade to the OTCQX® Best Market and believe this is a testament to the Predictive team who work to continuously improve our financial standards and corporate governance practices,” said Bradley C. Robinson, President and Chief Executive Officer of Predictive Technologies Group. “We welcome the broader investor reach and heightened visibility among the investment community that the OTCQX® Best Market confers on its traded companies.”
“We are pleased to be accepted to trade on the OTCQX Best Market. Our previously announced listing application for the NASDAQ Market exchange is currently in the review process,” Mr. Robinson concluded.
Burns Figa & Will PC acted as the company’s OTCQX sponsor.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Media Contact
Patrick Bursey
LifeSci Public Relations
pbursey@lifescipublicrelations.com
646-876-4932
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568
[h=1]The Bounce is On in Predictive Technology Group Inc (OTCMKTS
RED)[/h][FONT="]By James Hudson -
October 28, 2019[/FONT]
https://oracledispatch.com/2019/10/28/the-bounce-is-on-in-predictive-technology-group-inc-otcmktspred/
RED)[/h][FONT="]By James Hudson -October 28, 2019[/FONT]
https://oracledispatch.com/2019/10/28/the-bounce-is-on-in-predictive-technology-group-inc-otcmktspred/
[h=1]Predictive Technologies Group Engages LifeSci Partners as Communications Partner[/h][h=2]LifeSci to develop and execute comprehensive public relations and investor relations programs[/h][FONT="]https://www.globenewswire.com/news-...eSci-Partners-as-Communications-Partner.html#[FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT]Email [FONT="][/FONT]Print Friendly [FONT="][/FONT]Share
October 31, 2019 08:00 ET | Source: Predictive Technology Group Inc
SALT LAKE CITY, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCQX: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announced that it has engaged with LifeSci Partners (“LifeSci”) to increase awareness of the company’s brand and clinical programs.
“We are excited to work with LifeSci to inform the public and the investment community about our innovative data analytics that help physicians identify and combat diseases using our unique treatments and therapeutics,” said Bradley C. Robinson, president and chief executive officer of Predictive. “LifeSci’s expertise in investor relations and public relations, as well as their decades of experience in capital markets, media relations and scientific research have made them the perfect communications partner for our company as we work to grow our business and reach new audiences.”
LifeSci is a leading provider of strategic consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. LifeSci Advisors, LLC and LifeSci Public Relations will provide Predictive with integrated communications services through strategic messaging, investor and media outreach, social and digital media efforts.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit [url]www.predtechgroup.com[/URL].
About LifeSci Advisors
LifeSci Advisors is a division of LifeSci Partners (www.lifescipartners.com), a leading provider of consulting services for life sciences clients in the areas of investor relations, public relations, corporate communications, executive search, strategic partnering and capital markets advisory. LifeSci combines deep domain expertise and decades of experience in capital markets and communications with a global network to deliver unparalleled services to clients. LifeSci Advisors is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. LifeSci Advisor’s team of financial services and investor relations specialists synergistically pair with LifeSci Public Relations’ team of MDs and PhDs, positioning the firm to best communicate its clients’ scientific, R&D, regulatory and commercial strategies to diverse audiences. LifeSci Partners’ addition of executive search, strategic partnering and capital markets advisory capabilities provides fully integrated business solutions for life sciences clients across all stages of development.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit [url]www.predtechgroup.com[/URL] or contact:
Media Contact
Patrick Bursey
LifeSci Public Relations
pbursey@lifescipublicrelations.com
646-876-4932
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568
[/FONT]
PRED~
As you know we have been very bullish and an aggressive buyer of 2 specific stocks during the past number of months.
PRED~an emerging biotech/genetic test kit/ stem cell and potential drug developer has had a very rocky and even somewhat disappointing stock action to say the least.
We first recommended PRED at $2.13 and saw it run to $7.00 only to crash and burn slowly over the past number of months to the present price of $1.35.
We first get a Zack's report that was poorly written that never included any other business developments that PRED had been working on. Then we get this hit piece that was a complete sham that helped destroy the share price. Then we get the filing for NASDAQ listing which placed PRED in a news blackout for months and then finally we get the illegal "naked shorts" that have continued to slaughter the share price to its current depressed and severely undervalued pricing at $1.35. I don't intend to repeat all of the current and future developments and projects that PRED is involved with! Go and visit their website and review the complete story and connect the dots!
We now have 3 test kits being sold and the management is A+ that have migrated from some of the largest companies in the USA. The company has recently changed accounting firms and now has audits done by a top tier international firm. We have a agreement with TMO (Thermo Fisher) and recently signed an agreement with the largest brokerage firm in China (CITIC Securities Co ltd).
PRED's test kit for Endometriosis is going to be a BLOCK BUSTER! It is obvious that PRED is going to start marketing their ENDO in China. At present 10-15% of women in reproductive age are affected by this disease!
For a minute forget that paper losses are present for most investors in PRED at this time. Take a deep breath and start connecting the dots. At present there are almost 700 million women in China so it is easy to see how many women during their reproductive years develop this disease.
Please keep in mind that this is just one of their test kits. Visit their website http://www.predtechgroup.com The company has recently hired a new PR firm and has also listed on the OCTQX until the NASDAQ listing is completed. The QX exchange classifies qualified stocks as NOT being consided a "penny stock".
This designation allows a larger investor group including institutions the ability to buy PRED.
NASDAQ IS GOING TO HAPPEN
You never know when a "black swan' is going to appear for a stock, but PRED had 4 of them.
Zack's report, HB report, delay in NASDAQ which created a news blackout and the endless illegal "naked shorting"!
It is easy to see why this diamond in the rough looks like coal, but in reality is a gemstone for the picking! Of course we have entered tax selling season~So now we will deal with this scenario.
Don't take your eye-off-the-ball!
We continue to hear rumors that a major acquisition is in the works which could be announced before the end of the 2019. Please keep in mind another ER is due in about 2 weeks time, which should indicate growing stem cell sales and info on their newly introduced test kits ( 3 of the them).
If you like this stock at higher prices YOU must average down to lower your cost! We have made more money averaging down on investments than any other investment strategy. Do not panic, take a deep breath , & add to your position. It is only a matter of time before we reverse course and explode on the upside.
Lessons to be learned: We recommended HEMA @ .35 and it took awhile to get traction and three years later the stock trades @ $20.00
We recommended ARWR first @ $6.00 then it crashed to $2 and now around 3 years later the stock is $40.00. INVEST IN THE FUTURE NOT FOR TODAY!
We continue to pound the table on PRED and remain confident that this will be a huge winner overtime.
We rate PRED with our strongest buy rating @ current depressed and just "stupid " cheap levels Our target price remains at least $10 -$15.00 within 12 months or less .
Instead of "black swans" we start getting "unicorns" just watch what happens.
Well Pred finally went under a $1.00 today. Guess I better buy more today to bring my average buy amount down. Im for $3,000 at $2.97 buying $1500 in a few minutes hopefully at no more than $1.00. Going to keep trying to add small amounts while the price is dirt cheap. Hopefully things turn around 
Well Pred finally went under a $1.00 today. Guess I better buy more today to bring my average buy amount down. Im for $3,000 at $2.97 buying $1500 in a few minutes hopefully at no more than $1.00. Going to keep trying to add small amounts while the price is dirt cheap. Hopefully things turn around
I added as well. GL
